Asia
Chief Medical and Development Officer Debra Barker has decided to leave Polyphor at year end for personal reasons and will support on a part time basis afterwards.
Tan will lead the positioning of Cerecin’s pipeline of highly innovative neurotherapeutics
Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced that an application seeking manufacturing and marketing approval in Japan was submitted as of today by Meiji for the Parkinson’s disease treatment ME2125 (safinamide mesylate, “safinamide”).
October was a busy month as multiple biopharma companies made their debut as publicly traded entities and even more companies filed their intentions to go public with an initial public offering. BioSpace takes a look back at some of the key IPOs of the month.
Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that the two companies have commenced joint medical and marketing activities for tyrosine kinase inhibitor LENVIMA (generic name: lenvatinib mesylate) in Japan.
ASLAN Pharmaceuticals today announced the presentation of new data from an ongoing phase 1 study to determine the safety, tolerability and maximum tolerated dose (MTD) of varlitinib in combination with oxaliplatin and capecitabine (COX) or oxaliplatin and 5-FU (FOL) in advanced solid tumours.
Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more.
After releasing positive topline data from the Phase II study of BAN2401 as a potential treatment for Alzheimer’s disease in July, some of the numbers did not hold up. This morning Biogen and its developmental partner Eisai attempted to provide an update on the information to show that the anti-amyloid plaque treatment still has some life.
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
The new ‘Centre of Excellence’ already boasts one of the world’s most advanced gummy production line designed to meet demand from global markets
PRESS RELEASES